Ribon Therapeutics Stock

ribontx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $108.5MM

Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.

Register for Details

For more details on financing and valuation for Ribon Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Ribon Therapeutics.

Register Today

Team

Management Team

Paul Chang Ph.D
Scientific Co-Founder
Kevin Kuntz Ph.D
Vice President, Molecular Discovery
David Cordo
Chief Financial Officer
Victoria Richon Ph.D
President, Chief Executive Officer & Board Member
W. Kraus Ph.D
Scientific Co-Founder
Sudha Parasuraman MD
Chief Medical Officer
Tim Mitchison Ph.D
Scientific Co-Founder
Heike Keilhack Ph.D
Vice President of Biological Sciences
Edward Stewart
Chief Business Officer

Board Members

James Audia Ph.D
Anja König Ph.D
Novartis Venture Fund
Jonathan Root MD
US Venture Partners
William Harrington MD
Osage Venture Partners
Cameron Wheeler Ph.D
Deerfield Management
Laurence Lasky Ph.D
The Column Group
Marian Nakada
Peter Svennilson
The Column Group

Other companies like Ribon Therapeutics in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B
Updated on: Oct 2, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.